Table 3.
Systemic chemotherapy for unresectable PMP.
| Regimen | N. of Patients |
Median PFS (months) |
Median OS (months) |
RR (%) |
DCR (%) |
|---|---|---|---|---|---|
| Capecitabine/5FU [40] | 54 | 7.6 | 56 | 24 | 56 |
| Capecitabine + MMC [41] | 40 | nr | 84 | 8 | 42 |
| Capecitabine + Bevacizumab [42] | 15 | 8.2 | 91 a | 20 | 87 |
| Capecitabine + Ciclophosphamide [43] | 23 | 9.5 | 73.7 a | 4 | 87 |
| FOLFOX6 [44] | 8 | 8.0 | 26 | 20 | 65 |
a Percentage at 1 year. Abbreviations: PFS, progression-free survival; OS, overall survival; RR, response rate; DCR, disease control rate; 5FU, 5-Fluorouracil; MMC, Mitomycin C; nr, not reported.